Discovery medicine
-
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies without effective screening strategy during the early stage. Therefore, a novel screening panel was identified based on potential biomarkers associated with PDAC using the gene expression profile. The dataset GSE15471, which was downloaded from the Gene Expression Omnibus (GEO) database, included matching pairs of normal and tumor tissue samples from the resected pancreas of 39 pancreatic cancer patients. ⋯ Gene Expression Profiling Interactive Analysis (GEPIA) survival analysis showed that high expressions of KRT7, KRT19, SEMA3C, ITGA2, MYOF, and ANXA1 may predict poor survival outcome in PDAC. Finally, Oncomine confirmed that the high expressions of these genes were strongly related to cancer grade. These hub genes and regulators straightened out the molecular pathways and recurrence mechanisms in PDAC and could be used as targets for PDAC's diagnosis, treatment, and prognostic prediction.
-
The easy liver fibrosis test (eLIFT) is a novel index to assess advanced liver fibrosis in chronic liver diseases. We aimed to investigate the diagnostic accuracy of eLIFT for advanced liver fibrosis in patients with chronic hepatitis B (CHB). ⋯ eLIFT as a novel index can predict advanced liver fibrosis with a moderate sensitivity and accuracy in CHB patients. eLIFT, though having similar diagnostic values of advanced liver fibrosis compared to more complex existing tools such as APRI, FIB-4, GPR, and RPR in CHB patients, has the advantage of clarity of generation and ease of application and has the potential of being widely used by hepatologists.